Sleep-disordered breathing

Obstructive sleep apnea (OSA) is the repeated partial or complete collapse of the upper airway during sleep. Estimates place its prevalence at around 30–40% in middle-aged men and 15–20% in middle-aged women, and the majority of cases are undiagnosed. Each apneic event causes a brief oxygen drop, a sympathetic-nervous-system surge, and a partial arousal that fragments sleep architecture; people with severe OSA can have 30+ events per hour and never consciously notice. The downstream toll — accelerated cardiovascular aging, atrial fibrillation, resistant hypertension, dementia risk, type 2 diabetes, erectile dysfunction — falls quietly on what people otherwise experience as "I'm tired" or "I snore a bit." Treating it works, but only if it's identified first.

What OSA actually is

OSA is mechanical airway collapse during sleep — the tongue base, soft palate, and pharyngeal walls fall in when the muscles that hold them open relax. Each collapse drops blood oxygen, triggers a sympathetic spike, and produces a micro-arousal the sleeper rarely remembers. The clinical metric is the apnea-hypopnea index (AHI) — the average number of complete (apnea) or partial (hypopnea) airway obstructions per hour of sleep.^[1]

The mortality and morbidity signals are large. A 2016 meta-analysis of 27 cohort studies covering over 3 million adults found severe OSA associated with roughly double the all-cause mortality (hazard ratio ~2.13) and nearly triple the cardiovascular mortality (HR ~2.73) of unaffected adults.^[2] A 2025 Diagnostics update confirmed a clean dose-response for incident cardiovascular disease: ~21% higher risk in mild, ~56% in moderate, and ~145% in severe untreated OSA.^[3] Yaggi's landmark NEJM study found untreated moderate-to-severe OSA roughly doubled the risk of stroke or death over a six-year follow-up.^[4]

Why OSA accelerates aging at the cellular level

The damaging mechanism isn't the airway collapse itself — it's the intermittent hypoxia (IH) pattern of repeated oxygen drops followed by rapid re-oxygenation, hundreds of times per night, for years.

1. Reactive oxygen species (ROS) overload. The hypoxia-reoxygenation cycle mimics ischemia-reperfusion injury. Each cycle dumps superoxide and hydroxyl radicals faster than antioxidant enzymes (superoxide dismutase, catalase, glutathione) can clear them. OSA patients show measurably elevated 8-isoprostane and 8-hydroxydeoxyguanosine — clinical markers of oxidative damage to lipids and DNA.^[5]
2. HIF-1α and NF-κB activation. Repeated transient hypoxia chronically activates hypoxia-inducible factor 1-alpha (HIF-1α), which cross-talks with the inflammatory master switch NF-κB. The result: a steady release of tumour necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) into the systemic circulation — a low-grade chronic inflammatory state.
3. Endothelial dysfunction and accelerated vascular aging. The combined ROS-and-cytokine load strips arteries of nitric-oxide-mediated vasodilation, drives atherosclerosis, and produces the resistant hypertension phenotype that fails to respond well to standard antihypertensives. OSA is the most consistent treatable cause of medication-resistant hypertension.
4. Telomere attrition. Leukocyte telomere length shortens faster in adults with poor sleep and untreated OSA — a biomarker now broadly accepted to track biological aging across cardiovascular and oncological outcomes.

This is why OSA shows up as a multiplier on every major chronic-disease pathway downstream of inflammation and endothelial damage. The condition isn't producing one disease — it's accelerating most of them.

Who should screen

Major risk factors:

• Male sex (though women are markedly underdiagnosed; postmenopausal women catch up to male prevalence)
• Body mass index (BMI) ≥30
• Neck circumference above 43 cm in men or 40 cm in women
• Craniofacial anatomy — small or recessed jaw, narrow palate, large tongue, low-hanging soft palate
• Family history of OSA
• Alcohol or sedative use near bedtime
• Hypothyroidism, acromegaly, polycystic ovary syndrome (PCOS)

Symptoms (any one warrants a workup):

• Loud habitual snoring
• Witnessed apneas — a bed partner reports gasping, choking, or pauses in breathing
• Unrefreshing sleep, daytime sleepiness, falling asleep at the wheel
• Resistant hypertension (blood pressure poorly controlled on three or more drugs)
• Atrial fibrillation
• Morning headache
• Erectile dysfunction
• Nocturia (multiple wake-ups to urinate)

The STOP-Bang questionnaire

The most validated free screening tool is STOP-Bang — eight yes/no questions, three or more positives flags high risk.^[6]

• S — do you snore loudly?
• T — do you feel tired during the day?
• O — has anyone observed you stop breathing in your sleep?
• P — high blood pressure (treated or untreated)?
• B — body mass index over 35?
• A — age over 50?
• N — neck circumference larger than 40 cm?
• G — male gender?

Three or more "yes" answers → ask for a sleep study.

Home sleep testing is now first-line

Home sleep apnea testing (HSAT) is the standard first-line study for most adults without major medical comorbidity — a small device worn overnight at home, accurate enough to confirm or rule out OSA at a fraction of the cost of an in-lab study. Full in-lab polysomnography (PSG) is reserved for complex cases, suspected central sleep apnea, or when home testing is inconclusive.

Treatment: CPAP is first-line

Continuous positive airway pressure (CPAP) — a small pump that delivers a steady stream of pressurised air through a mask, mechanically splinting the airway open — is first-line for moderate-to-severe OSA.^[7]

The single biggest determinant of outcomes is adherence: at least 4 hours per night on at least 70% of nights. About 30–50% of patients struggle to reach this on their first attempt. Modern auto-adjusting (APAP) machines, well-fitted masks (nasal pillows, full face, hybrid), heated humidification, and proper clinician follow-up dramatically improve adherence; if the first setup doesn't work, the answer is usually a different mask, not abandoning therapy.

Adherent CPAP reliably reduces daytime sleepiness, lowers ambulatory blood pressure (especially in resistant hypertension), reduces motor vehicle accident rates, and reduces atrial fibrillation recurrence after ablation. The cardiovascular outcome picture is more nuanced. The SAVE trial (2016) — the largest randomised trial of CPAP for cardiovascular event prevention — was negative on its primary endpoint, but mean adherence was only 3.3 hours per night in the CPAP arm. Subsequent analyses adjusting for actual usage show meaningful CV benefit at the ≥4-hour mark. The current standard interpretation: CPAP works when it's actually used; the trial was a negative trial of partial CPAP exposure, not a negative trial of the therapy.

Alternatives when CPAP isn't tolerated

The nasal breathing physiology

A theme that's emerged in the modern OSA literature is that how you breathe even outside of apneic events matters. Nasal breathing is the physiological default; chronic mouth breathing is its own risk factor.

Mechanics. Total pharyngeal airway resistance during sleep is actually lower with nasal breathing than oral breathing. Mouth breathing drops the jaw, lowers the tongue, and increases the gravitational pull on the soft palate — anatomically increasing the airway's tendency to collapse. The cleanest signal in the literature: even in patients with documented OSA, the oral breathing route during sleep is associated with measurably more severe events than the same patient's nasal route.

Nitric oxide. The paranasal sinuses continuously produce nitric oxide (NO) — the same vasodilator the cardiovascular system depends on. Concentrations from the nose run around 56 parts per billion, versus ~14 from the mouth and ~6 from the trachea. During nasal inspiration, that NO is swept into the lungs, where it preferentially dilates pulmonary blood vessels in well-ventilated alveoli, improving ventilation–perfusion matching. Transcutaneous oxygen tension runs ~10% higher on nasal-only versus oral-only breathing at rest. In intubated patients, reintroducing nasally-derived NO into the ventilator circuit produces an 18% rise in arterial oxygenation. Mouth breathing chronically bypasses this NO reservoir — a measurable cardiovascular cost on top of the airway mechanics.

Autonomic tone. Nasal breathing engages the diaphragm and pulmonary stretch receptors, which feed afferent signals to the vagus nerve and increase parasympathetic ("rest and recover") tone. Mouth breathing tends toward shallow, upper-chest patterns that favour sympathetic dominance. Across a night, that's a non-trivial dose of unnecessary stress signalling.

Mouth taping — the honest assessment

The viral practice of taping the lips shut at night to force nasal breathing has the right physiological intent and a complicated evidence base. The 2024 American Academy of Sleep Medicine commentary explicitly warned against unsupervised mouth taping outside of a clinical evaluation.

• The mechanistic case is real. If your mouth opens at night because you're missing a clinically diagnosable obstruction (deviated septum, allergic rhinitis, turbinate hypertrophy), forcing nasal breathing without addressing the underlying obstruction risks asphyxiation — a documented if rare adverse event.
• The clinical efficacy data is thin and mixed. A small number of studies in mild OSA show modest AHI improvement with chin straps or lip-occlusion devices; others show no benefit.^[8] The cleanest defensible use case is a person who has been medically evaluated, has clear nasal patency, and has a clinician-confirmed habit of mouth breathing without underlying obstruction.
• The risk-asymmetric failure mode. A 60-year-old with mild snoring who tapes their mouth shut and also has undiagnosed nasal polyps is the case report no one wants to be.

The right sequence for a mouth-breathing sleeper:

1. Get an ear-nose-throat (ENT) evaluation for nasal obstruction (deviated septum, polyps, turbinate hypertrophy, chronic rhinitis).
2. Get screened for OSA if any STOP-Bang risk is present.
3. Treat allergic rhinitis with intranasal corticosteroids or antihistamines.
4. Try side-sleeping first — reduces both snoring and AHI in supine-dominant OSA.
5. Consider orofacial myofunctional therapy if mouth breathing is muscular rather than structural.
6. Mouth taping only after the above are evaluated, ideally on a clinician's advice.

Orofacial myofunctional therapy (OMT)

OMT is a daily exercise programme that retrains the tongue, lips, cheeks, and pharyngeal muscles to maintain a correct resting posture — lips sealed, tongue flat against the hard palate, breathing nasally. In meta-analyses, OMT reduces AHI by roughly 50% in adults and 62% in children, also improves minimum oxygen saturation, and reduces snoring and daytime sleepiness.^[9] It's now widely accepted as a meaningful adjunct to CPAP, MADs, and post-surgical care — improving CPAP tolerance and cementing surgical outcomes. It's not a substitute for first-line therapy in moderate-to-severe OSA, but it's a reasonable standalone option for mild cases and a high-yield add-on to other therapies. Available through specially trained dentists, speech-language pathologists, and physical therapists.

Practical guidance

1. Take the STOP-Bang. If three or more answers are "yes," ask for a sleep study. Home sleep apnea testing is enough for most adults to confirm or rule out OSA — it's not the in-lab nightmare it used to be.
2. If your bed partner reports gasping, choking, or pauses, go straight to the sleep study. Witnessed apneas are the single most specific symptom and shouldn't be ignored.
3. Consider OSA whenever you encounter resistant hypertension, atrial fibrillation, or unexplained morning headache. The diagnostic yield in these subgroups is high enough that screening is now standard cardiology and primary-care practice.
4. If you're diagnosed, aim for ≥4 hours of CPAP per night on at least 70% of nights. Adherence is everything. If the mask isn't working, ask for a different one rather than giving up.
5. Lose weight if obesity-driven. Each 10% BMI reduction improves AHI ~25%. GLP-1 receptor agonists are now an option for adults who qualify — see Ozempic-class drugs.
6. Sleep on your side if events cluster supine. Tennis-ball-in-the-pyjama trick works; commercial positional devices do too.
7. Address nasal obstruction before considering mouth taping. ENT eval, treat the rhinitis or septum, then re-evaluate.
8. Don't drink alcohol within three hours of bed if you have OSA — alcohol relaxes upper airway muscles and worsens events.
9. For mild OSA or as a CPAP adjunct, ask about orofacial myofunctional therapy. The evidence is strong enough to be more than a niche option.

What's overrated

• Mouth taping as a first-line intervention without clinical evaluation. Defensible after an ENT cleared you; risky as a viral biohack.
• Snoring apps that "diagnose" OSA. Acoustic snoring metrics correlate poorly with AHI in research-grade data. Use them to motivate the sleep study, not as a substitute for it.
• "Sleeping pills for snoring." Sedatives that relax airway muscles make OSA worse, not better. Sleep aids in undiagnosed snorers are a documented harm signal.
• CBD, magnesium, or melatonin as treatments for OSA. Useful for general sleep quality in some adults (see sleep supplements); no effect on the airway mechanics that define OSA.
• Single nostril breathing techniques as OSA therapy. Useful for autonomic training in waking hours; not a substitute for treating mechanical airway collapse during sleep.

Further reading

• Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnoea — literature-based analysis. Lancet Respir Med 2019.^[10]
• Yaggi HK et al. Obstructive sleep apnea as a risk factor for stroke and death. NEJM 2005.^[11]
• OSA and cardiovascular mortality — meta-analysis of 27 cohorts. 2016.^[12]
• OSA cardiovascular outcomes update. Diagnostics 2025.^[13]
• Patil SP et al. Treatment of Adult OSA With Positive Airway Pressure — AASM Clinical Practice Guideline. J Clin Sleep Med 2019.^[14]
• Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM 2024.^[15]
• Mouth closure and airflow in OSA — clinical evaluation of mouth taping.^[16]
• STOP-Bang screening questionnaire (validated screening tool).^[17]
• Obstructive Sleep Apnea — StatPearls.^[18]